Radiographic and clinical changes of the patellar tendon after tibial plateau leveling osteotomy 94 cases (2000-2003).

Patellar tendon thickening (PTT) and patellar tendinosis (PTS) have been discussed in the veterinary literature as a post-operative complication of tibial plateau leveling osteotomy (TPLO). The purpose of this study was to define radiographic PTT, determine the frequency of and risk factors for PTT and PTS, and describe the clinical and histopathological findings of PTS after TPLO. We hypothesized that the location of the osteotomy alters forces placed on the patelloar tendon resulting in PTT or PTS. Radiographs and medical records from 83 dogs undergoing 94 TPLO procedures were retrospectively evaluated. Two months post-operatively, 19 dogs (20.2%) had a normal patellar tendon or mild PTT, 51 (54.3%) had moderate PTT, and 24 (25.5%) had severe PTT. Seven of the 24 dogs (7.4%) with severe PTT had clinical signs consistent with PTS. Only dogs with severe PTT developed PTS (p < 0.0001). The risk factors for the development of PTT include: a cranial osteotomy, a partially intact cranial cruciate ligament (CCL) in conjunction with a cranial osteotomy, and post-operative tibial tuberosity fracture. The only risk factor identified for the development of PTS was a partially intact CCL. Four dogs with PTS improved with conservative therapy and one improved with surgical treatment. Two dogs had tendon biopsies with histopothological review that showed tendon degeneration with lack of inflammation. As only the dogs with severe PTT develop PTS, a caudal osteotomy for the prevention of PTT and subsequent PTS is recommended.

Efficacy of imidacloprid for removal and control of fleas (Ctenocephalides felis) on dogs.

OBJECTIVE: To evaluate efficacy of a 9.1% (w/w) imidacloprid solution, applied topically, to remove fleas from dogs and the duration of residual flea control when dogs were exposed to continuing flea infestation. ANIMALS: 32 adult mixed-breed dogs. PROCEDURE: Dogs were allocated to 4 groups of 8 dogs each; dogs of 3 groups received a single dose of imidacloprid, and those of the fourth group received excipient. Each dog was infested with 100 adult fleas on study days -3, -1, 6, 13, 20, 27, and 33. Treatments were applied on day 0. Each dog was examined for live fleas on days -2, 1, 7, 14, 21, 28, and 34. Posttreatment efficacy was determined by comparing the mean number of live fleas remaining on the treated dogs with the mean number of live fleas remaining on the control dogs. RESULTS: All 3 imidacloprid dosages provided flea control > or = 96.9% one day after treatment. Maximal efficacy of all 3 dosages (99.1 to 100%) was observed at 7 days after treatment. Flea control with 3.75 mg of imidacloprid/kg of body weight ranged from 94.4 to 96.9% for days 14 to 28 and decreased to 91.6% by 34 days after treatment. Flea control with 7.5 and 10.0 mg of imidacloprid/kg was 97.8 to 100% through day 28. At day 34, dosages of 7.5 and 10.0 mg of imidacloprid/kg were 97.6 and 96.9% efficacious, respectively. CONCLUSION: 7.5 or 10.0 mg of imidacloprid/kg are equivalent and superior to 3.75 mg/kg for flea control over the course of a 34 day posttreatment period. CLINICAL RELEVANCE: Monthly imidacloprid application of 7.5 to 10 mg/kg will rapidly kill existing and reinfesting flea infestations on dogs and break the flea life cycle by killing adult fleas before egg production begins.

Serum haptoglobin concentration in swine naturally or experimentally infected with Actinobacillus pleuropneumoniae.

Serum haptoglobin (Hp) concentrations were measured in swine that were naturally or experimentally infected with Actinobacillus pleuropneumoniae. In swine from a specific-pathogen-free herd, mean serum concentration of Hp (+/- SD) was 5.79 +/- 1.06 mg of cyanmethemoglobin-binding capacity (CHBC)/dl. Serum Hp concentrations in paired samples were measured at 7-day intervals in 40 swine randomly selected from a conventional herd that was experiencing an acute episode of pneumonia and deaths caused by A pleuropneumoniae serotype-5 infection. Day-0 and -7 serum Hp concentrations were 24.58 +/- 1.38 and 23.10 +/- 1.12 mg of CHBC/dl, respectively, with no significant difference between these measurements. In a second conventional herd with a history of chronic infection with A pleuropneumoniae serotype 5, serum concentrations of Hp measured in paired samples obtained 6 days apart were 12.36 +/- 0.81 and 18.63 +/- 0.76 mg of CHBC/dl, respectively, and were significantly (P < 0.05) different from each other. Twenty-nine 12-week-old conventional swine were challenged intranasally with A pleuropneumoniae serotype 1 (n = 19) and serotype 5 (n = 10). Serum Hp concentration increased from prechallenge concentrations of 7.49 +/- 1.38 and 15.10 +/- 1.22 mg of CHBC/dl, respectively, to 41.01 +/- 1.35 and 22.37 +/- 1.78 mg of CHBC/dl, respectively, 72 hours after challenge. For these 29 swine, serum Hp concentration was positively correlated with rectal temperature (r = 0.34; P < 0.001) during the immediate postchallenge period.

Progress after one year of a pseudorabies eradication program for large swine herds.

Six large farrow-to-finish swine herds quarantined for pseudorabies in Illinois participated in the USDA-initiated Large Herd Cleanup Study. These herds were monitored for antibodies to pseudorabies virus (PRV) for 1 year after the initiation of an intensive eradication program. Herd size ranged between 425 and 1,500 females of breeding age. Gene-deleted modified-live virus vaccines were used on all farms, with 3 of the 6 herds receiving a vaccine with a deletion of the gene for glycoprotein-I and the other 3 herds receiving a vaccine with a deletion of the gene for glycoprotein-X. The breeding herd and growing pigs were vaccinated on each farm. Each herd produced its own replacement gilts. In addition, management changes emphasizing all-in, all-out pig flow were initiated. One year after initiation of the vaccination program, sera for the measurement of PRV antibodies were obtained from sows and heavy finishing pigs (> 70 kg) from each of the farms. Prevalence of PRV antibodies attributable to wild-type virus infection ranged from 7 to 63% (median, 33%) for sows and from 0 to 42% (median, 4%) for finishers, as determined by the appropriate vaccine differential test. For each sow herd, there was a large decrease in the PRV seroprevalence rate after 1 year of the program (range, -21 to -68%; median, -42%). Examination of PRV prevalence rates by parity indicated decreased seroprevalences in the lower parities (< 2) in 3 of the herds, suggesting that vaccination reduced the spread of PRV.(ABSTRACT TRUNCATED AT 250 WORDS)

Effect of long-term administration of an injectable enrofloxacin solution on physical and musculoskeletal variables in adult horses.

OBJECTIVE: To evaluate clinical safety of administration of injectable enrofloxacin. DESIGN: Randomized controlled clinical trial. ANIMALS: 24 adult horses. PROCEDURES: Healthy horses were randomly allocated into 4 equal groups that received placebo injections (control) or IV administration of enrofloxacin (5 mg/kg [2.3 mg/lb], 15 mg/kg [6.8 mg/lb], or 25 mg/kg [11.4 mg/lb] of body weight, q 24 h) for 21 days. Joint angles, cross-sectional area of superficial and deep digital flexor and calcaneal tendons, carpal or tarsal osteophytes or lucency, and midcarpal and tarsocrural articular cartilage lesions were measured. Physical and lameness examinations were performed daily. Measurements were repeated after day 21, and articular cartilage and bone biopsy specimens were examined. RESULTS: Enrofloxacin did not induce changes in most variables during administration or for 7 days after administration. One horse (dosage, 15 mg/kg) developed lameness and cellulitis around the tarsal plantar ligament during the last week of administration. One horse (dosage, 15 mg/kg) developed mild superficial digital flexor tendinitis, and 1 horse (dosage, 25 mg/kg) developed tarsal sheath effusion without lameness 3 days after the last administration. High doses of enrofloxacin (15 and 25 mg/kg) administered by bolus injection intermittently induced transient neurologic signs that completely resolved within 10 minutes without long-term effects. Slower injection and dilution of the dose ameliorated the neurologic signs. Adverse reactions were not detected with a 5 mg/kg dose administered IV as a bolus. CONCLUSIONS AND CLINICAL RELEVANCE: Enrofloxacin administered IV once daily at the rate of 5 mg/kg for 3 weeks is safe in adult horses.